Although improvement of endothelial dysfunction with a single administration of vildagliptin has been reported [33], in fact the reported short-term effects of treatment with DPP-4 inhibitors on FMD have been controversial [20, 34–38]. The gene discussed is DPP4; the disease is endothelial dysfunction.